An Aberrant Inflammatory Response in Severe COVID-19

Overview

Journal Cell Host Microbe

Publisher Cell Press

Specialties Infectious Diseases
Microbiology

Date 2021 Jul 15

PMID 34265243

Citations 23

Authors

Miriam Merad

Aruna Subramanian

Taia T Wang

Affiliations

Soon will be listed here.

Abstract

Severe COVID-19 arises from the convergence of inadequate pre-existing immunity and a host response that damages, rather than repairs, tissues. We outline clinical presentations of COVID-19 that are likely driven by dysregulated host immunity, discuss potential mechanisms underlying pathological responses, and highlight important areas for basic research on this topic.

Citing Articles

Linear ubiquitination mediates coronavirus NSP14-induced NF-κB activation.

Hua F, Hao W, Wang L, Song K, Hasan A, Wu Y Cell Commun Signal. 2024; 22(1):573.

PMID: 39616385 PMC: 11607897. DOI: 10.1186/s12964-024-01949-4.

COVID-19 vaccines: current and future challenges.

Mohammadi D, Ghasemi M, Manouchehrian N, Zafarmand M, Akbari M, Boroumand A Front Pharmacol. 2024; 15:1434181.

PMID: 39568586 PMC: 11576167. DOI: 10.3389/fphar.2024.1434181.

Risk Factors for Secondary Organizing Pneumonia and Acute Fibrinous and Organizing Pneumonia in Patients with COVID-19 Pneumonia.

Aikwanich A, Eksombatchai D, Petnak T, Tassaneeyasin T, Boonsarngsuk V Infect Drug Resist. 2024; 17:5017-5026.

PMID: 39554470 PMC: 11566205. DOI: 10.2147/IDR.S481540.

Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes.

Viode A, Smolen K, van Zalm P, Stevenson D, Jha M, Parker K Sci Adv. 2024; 10(21):eadl5762.

PMID: 38787940 PMC: 11122669. DOI: 10.1126/sciadv.adl5762.

Understanding the Impact of COVID-19 on Roma Vulnerable Communities in Western Romania: Insights and Predictive Factors from a Retrospective Study.

Capraru I, Marian C, Vulcanescu D, Tanasescu S, Dragomir T, Marti T Viruses. 2024; 16(3).

PMID: 38543800 PMC: 10974346. DOI: 10.3390/v16030435.

References

Zheng M, Karki R, Williams E, Yang D, Fitzpatrick E, Vogel P . TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22(7):829-838. PMC: 8882317. DOI: 10.1038/s41590-021-00937-x. View

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J . Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857407. DOI: 10.1126/science.abd4570. View

Melms J, Biermann J, Huang H, Wang Y, Nair A, Tagore S . A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021; 595(7865):114-119. PMC: 8814825. DOI: 10.1038/s41586-021-03569-1. View

Bogunovic D, Merad M . Children and SARS-CoV-2. Cell Host Microbe. 2021; 29(7):1040-1042. PMC: 8279573. DOI: 10.1016/j.chom.2021.06.015. View

Bastard P, Rosen L, Zhang Q, Michailidis E, Hoffmann H, Zhang Y . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857397. DOI: 10.1126/science.abd4585. View

Bergamaschi L, Mescia F, Turner L, Hanson A, Kotagiri P, Dunmore B . Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021; 54(6):1257-1275.e8. PMC: 8125900. DOI: 10.1016/j.immuni.2021.05.010. View

Gaebler C, Wang Z, Lorenzi J, Muecksch F, Finkin S, Tokuyama M . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591(7851):639-644. PMC: 8221082. DOI: 10.1038/s41586-021-03207-w. View

10.

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

11.

Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco A, Sherwood R . Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2020; 22(1):67-73. PMC: 8130642. DOI: 10.1038/s41590-020-00828-7. View

12.

Saichi M, Ladjemi M, Korniotis S, Rousseau C, AIt Hamou Z, Massenet-Regad L . Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. Nat Cell Biol. 2021; 23(5):538-551. DOI: 10.1038/s41556-021-00681-2. View

13.

Yamin R, Jones A, Hoffmann H, Schafer A, Kao K, Francis R . Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. 2021; 599(7885):465-470. PMC: 9038156. DOI: 10.1038/s41586-021-04017-w. View

14.

Del Valle D, Kim-Schulze S, Huang H, Beckmann N, Nirenberg S, Wang B . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-1643. PMC: 7869028. DOI: 10.1038/s41591-020-1051-9. View

15.

Rosas I, Brau N, Waters M, Go R, Hunter B, Bhagani S . Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021; 384(16):1503-1516. PMC: 7953459. DOI: 10.1056/NEJMoa2028700. View